Article
Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men.
Pharmacogenetics - 1 Jan 2004
Maitland-van der Zee Anke Hilse, Klungel Olaf H, Stricker Bruno H Ch, Veenstra David L, Kastelein John J P, Hofman Albert, Witteman Jacqueline C M, Leufkens Hubertus G M, van Duijn Cornelia M, de Boer Anthonius
Abstract excerpt
This study aimed to assess the potential cost-effectiveness of screening men for their angiotensin-converting enzyme (ACE)-genotype before starting statin therapy. We used a combination of decision-analytic and Markov modelling techniques to evaluate the long-term incremental clinical and economic effects associated with genetic testing of men with hypercholesterolemia before starting treatment with statins. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.